Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why ; volume:11 ; number:1 ; day:31 ; month:5 ; year:2018 ; pages:1-13 ; date:12.2018
Journal of hematology & oncology ; 11, Heft 1 (31.5.2018), 1-13, 12.2018
- Creator
-
Derenzini, Enrico
- Contributor
-
Rossi, Alessandra
Treré, Davide
SpringerLink (Online service)
- DOI
-
10.1186/s13045-018-0609-1
- URN
-
urn:nbn:de:101:1-2018080722180908612482
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Derenzini, Enrico
- Rossi, Alessandra
- Treré, Davide
- SpringerLink (Online service)
Other Objects (12)
Inhibiting eukaryotic ribosome biogenesis
The nucleolus and ribosome biogenesis
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies
Deubiquitinases in hematological malignancies
Checkpoint inhibitors in hematological malignancies
Rac GTPases in hematological malignancies
Hematological Malignancies and Arterial Thromboembolism
Mitochondrial transfer in hematological malignancies
Evolution of the holozoan ribosome biogenesis regulon
Ribosome biogenesis factors—from names to functions
Targeting immune checkpoints in hematological malignancies
Cellular immunotherapy for refractory hematological malignancies
Inhibiting eukaryotic ribosome biogenesis
The nucleolus and ribosome biogenesis
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies
Deubiquitinases in hematological malignancies
Checkpoint inhibitors in hematological malignancies
Rac GTPases in hematological malignancies
Hematological Malignancies and Arterial Thromboembolism
Mitochondrial transfer in hematological malignancies
Evolution of the holozoan ribosome biogenesis regulon
Ribosome biogenesis factors—from names to functions
Targeting immune checkpoints in hematological malignancies
Cellular immunotherapy for refractory hematological malignancies
Inhibiting eukaryotic ribosome biogenesis
The nucleolus and ribosome biogenesis
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies
Deubiquitinases in hematological malignancies
Checkpoint inhibitors in hematological malignancies
Rac GTPases in hematological malignancies
Hematological Malignancies and Arterial Thromboembolism
Mitochondrial transfer in hematological malignancies
Evolution of the holozoan ribosome biogenesis regulon
Ribosome biogenesis factors—from names to functions
Targeting immune checkpoints in hematological malignancies